全文获取类型
收费全文 | 1431753篇 |
免费 | 101364篇 |
国内免费 | 2273篇 |
专业分类
耳鼻咽喉 | 20794篇 |
儿科学 | 47426篇 |
妇产科学 | 41615篇 |
基础医学 | 209706篇 |
口腔科学 | 40029篇 |
临床医学 | 120725篇 |
内科学 | 279773篇 |
皮肤病学 | 30597篇 |
神经病学 | 114132篇 |
特种医学 | 57583篇 |
外国民族医学 | 391篇 |
外科学 | 222739篇 |
综合类 | 27445篇 |
现状与发展 | 1篇 |
一般理论 | 352篇 |
预防医学 | 101088篇 |
眼科学 | 32936篇 |
药学 | 108668篇 |
1篇 | |
中国医学 | 2913篇 |
肿瘤学 | 76476篇 |
出版年
2018年 | 15034篇 |
2017年 | 11448篇 |
2016年 | 13299篇 |
2015年 | 15068篇 |
2014年 | 19673篇 |
2013年 | 29775篇 |
2012年 | 42255篇 |
2011年 | 44749篇 |
2010年 | 26002篇 |
2009年 | 23724篇 |
2008年 | 43253篇 |
2007年 | 46911篇 |
2006年 | 47434篇 |
2005年 | 46804篇 |
2004年 | 44936篇 |
2003年 | 43815篇 |
2002年 | 43038篇 |
2001年 | 62776篇 |
2000年 | 64286篇 |
1999年 | 54567篇 |
1998年 | 15520篇 |
1997年 | 13889篇 |
1996年 | 13909篇 |
1995年 | 13063篇 |
1994年 | 12393篇 |
1993年 | 11477篇 |
1992年 | 42665篇 |
1991年 | 42023篇 |
1990年 | 41530篇 |
1989年 | 40211篇 |
1988年 | 37377篇 |
1987年 | 36620篇 |
1986年 | 34923篇 |
1985年 | 33324篇 |
1984年 | 24857篇 |
1983年 | 21556篇 |
1982年 | 12922篇 |
1981年 | 11415篇 |
1979年 | 23616篇 |
1978年 | 16597篇 |
1977年 | 14364篇 |
1976年 | 13511篇 |
1975年 | 14983篇 |
1974年 | 17502篇 |
1973年 | 16827篇 |
1972年 | 16067篇 |
1971年 | 14931篇 |
1970年 | 13835篇 |
1969年 | 13320篇 |
1968年 | 12558篇 |
排序方式: 共有10000条查询结果,搜索用时 109 毫秒
91.
92.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
93.
94.
95.
J. Savige L. Amos Frank Ierino H. G. Mack R. C. Andrew Symons P. Hughes 《Ophthalmic genetics》2016,37(4):369-376
Background: Dense deposit disease and atypical hemolytic uremic syndrome are often caused by Complement Factor H (CFH) mutations. This study describes the retinal abnormalities in dense deposit disease and, for the first time, atypical haemolytic uremic syndrome. It also reviews our understanding of drusen pathogenesis and their relevance for glomerular disease. Methods: Six individuals with dense deposit disease and one with atypical haemolytic uremic syndrome were studied from 2 to 40 years after presentation. Five had renal transplants. All four who had genetic testing had CFH mutations. Individuals underwent ophthalmological review and retinal photography, and in some cases, optical coherence tomography, and further tests of retinal function. Results: All subjects with dense deposit disease had impaired night vision and retinal drusen or whitish-yellow deposits. Retinal atrophy, pigmentation, and hemorrhage were common. In late disease, peripheral vision was restricted, central vision was distorted, and there were scotoma from sub-retinal choroidal neovascular membranes and atypical serous retinopathy. Drusen were present but less prominent in the young person with atypical uremic syndrome due to a heterozygous CFH mutation. Conclusions: Drusen are common in forms of C3 glomerulopathy caused by compound heterozygous or heterozygous CFH mutations. They are useful diagnostically but also impair vision. Drusen have an identical composition to glomerular deposits. They are also identical to the drusen of age-related macular degeneration, and may respond to the same treatments. Individuals with a C3 glomerulopathy should be assessed ophthalmologically at diagnosis, and monitored regularly for vision-threatening complications. 相似文献
96.
A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases
下载免费PDF全文
![点击此处可从《Journal of the European Academy of Dermatology and Venereology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
97.
98.
Turnbull Chris D. Stockley James A. Madathil Shyam Huq Syed S. A. Cooper Brendan G. Ali Asad Wharton Simon Stradling John R. Heitmar Rebekka 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(7):2129-2139
Graefe's Archive for Clinical and Experimental Ophthalmology - Retinal microvascular endothelial dysfunction is thought to be of importance in the development of ocular vascular diseases.... 相似文献
99.
100.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献